Singapore markets close in 1 hour 21 minutes

Marpai, Inc. (MRAI)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0500+0.0100 (+0.96%)
At close: 04:00PM EDT
1.0400 -0.01 (-0.95%)
After hours: 06:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0400
Open1.0658
Bid0.0000 x 900
Ask0.0000 x 2900
Day's range1.0300 - 1.0658
52-week range0.6930 - 6.3100
Volume7,604
Avg. volume184,804
Market cap21.717M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.3950
Earnings date11 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.50
  • Business Wire

    Marpai, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

    TAMPA, Fla., January 07, 2022--Marpai, Inc. (NASDAQ: MRAI), a deep learning technology company transforming third party administration in the self-funded health insurance market, today announced that an interview with CEO Edmundo Gonzalez will air on The RedChip Money Report® on Bloomberg TV on Saturday, Jan. 8 at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

  • Business Wire

    Marpai, Inc. Insiders Buy $1.1 Million of Common Stock

    NEW YORK, December 20, 2021--Marpai, Inc. ("Marpai" or the "Company") (NASDAQ: MRAI), a deep learning technology company transforming third party administration (TPA) in the self-funded health insurance market, today announced the Company’s management and directors purchased $1.1 million of Marpai common stock.

  • Business Wire

    Marpai, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option

    TAMPA, Fla., October 29, 2021--Marpai, Inc. (the "Company") (Nasdaq: MRAI), a deep learning technology company transforming third party administration in the healthcare self-funded market, today announced the closing of its initial public offering of 7,187,500 shares of its common stock at a public offering price of $4.00 per share, including 937,500 shares sold upon full exercise of the underwriters’ over-allotment option, for gross proceeds of $28.75 million, before deducting underwriting disc